Greenberg 1981

Methods	RCT Length of follow‐up: 11 months
Participants	All children living in endemic area Number analysed for primary outcome: 152 aged 1.5 to 8 years Age range: 1.5 to 8 years Inclusion criteria: children aged 1.5 to 8 years living in Nandipara, Bangladesh; 50% entered into trial; only those who provided stool sample and had anthropometric measurements taken at first visit entered Exclusion criteria: none stated
Interventions	Single dose vs placebo Piperazine citrate: 80 mg/kg added to flavoured syrup; 2 doses in 2‐week period; Placebo: syrup only.
Outcomes	Cure rates; Reinfection rates; Weight‐for‐height; Height‐for‐age (NCHS reference); Weight‐for‐age (graphically); Other measured parameters not reported: weight; height; triceps skinfold thickness; MUAC; chest circumference; abdominal girth; egg counts (Dunn's method); prevalence; triceps skinfold for age; MUAC for age (Tanner reference charts).
Notes	Location: Bangladesh Community category: 1 Groups stratified by intensity of Ascaris infection Source of funding not reported.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Randomly assigned", no further details provided.
Allocation concealment (selection bias)	Unclear risk	No details reported.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	"Double‐blind". Participants blinded both placebo and treatment given as a flavoured syrup, no information about provider and assessor blinding.
Incomplete outcome data (attrition bias) All outcomes	Low risk	82% (152/185) of randomized participants were evaluated. Reasons for leaving the trial early not reported. Inclusion of all randomized participants (number evaluable/number randomized): 82% (152/185).
Selective reporting (reporting bias)	High risk	Not all stated outcomes reported.
Other bias	Low risk	No obvious other source of bias.